Synonym
2-Phenylaminoadenosine; CV-1808; CV 1808; CV1808; LSU 165; LSU-165; LSU165;
IUPAC/Chemical Name
(2R,3R,4S,5R)-2-[6-amino-2-(phenylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
InChi Key
SCNILGOVBBRMBK-SDBHATRESA-N
InChi Code
InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)/t9-,11-,12-,15-/m1/s1
SMILES Code
O[C@H]1[C@H](N2C=NC3=C(N)N=C(NC4=CC=CC=C4)N=C23)O[C@H](CO)[C@H]1O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
358.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cornfield LJ, Hu S, Hurt SD, Sills MA. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther. 1992 Nov;263(2):552-61. PubMed PMID: 1331404.
2: Hardart GE, Sullivan GW, Carper HT, Mandell GL. Adenosine and 2-phenylaminoadenosine (CV-1808) inhibit human neutrophil bactericidal function. Infect Immun. 1991 Mar;59(3):885-9. PubMed PMID: 1847698; PubMed Central PMCID: PMC258343.
3: Tanabe M, Terashita Z, Nishikawa K, Hirata M. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):442-8. PubMed PMID: 6202970.
4: Taylor DA, Williams M. Interaction of 2-phenylaminoadenosine (CV 1808) with adenosine systems in rat tissues. Eur J Pharmacol. 1982 Dec 3;85(3-4):335-8. PubMed PMID: 6295788.
5: Hayashi Y, Miyake S, Kuwayama M, Hattori M, Usui Y. Quantitation of 6-amino-2-phenylamino-9-beta-D-ribofuranosyl-9-H-purine (CV-1808) and its metabolite, 2-(2-hydroxyphenyl)aminoadenosine, in human serum and urine by high performance liquid chromatography using a fluorimetric detector. Chem Pharm Bull (Tokyo). 1982 Nov;30(11):4107-13. PubMed PMID: 7165879.
6: Matsumoto N, Kawazoe K, Tanabe M, Imamoto T, Fujiwara S, Hirata M. Effect of 2-phenylaminoadenosine (CV-1808) on ischemic ST-segment elevation in anesthetized dogs. J Cardiovasc Pharmacol. 1981 Nov-Dec;3(6):1184-92. PubMed PMID: 6173517.
7: Kawazoe K, Matsumoto N, Tanabe M, Fujiwara S, Yanagimoto M, Hirata M, Kikuchi K. Coronary and cardiohemodynamic effects of 2-phenylamino-adenosine (CV-1808) in anesthetized dogs and cats. Arzneimittelforschung. 1980;30(7):1083-7. PubMed PMID: 7191290.
